{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T19:47:30Z","timestamp":1789069650829,"version":"build-2803163510"},"reference-count":22,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"31","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2016,8]]},"DOI":"10.1097\/md.0000000000004330","type":"journal-article","created":{"date-parts":[[2016,8,10]],"date-time":"2016-08-10T20:06:24Z","timestamp":1470859584000},"page":"e4330","source":"Crossref","is-referenced-by-count":19,"title":["Can eculizumab be discontinued in aHUS?"],"prefix":"10.1097","volume":"95","author":[{"given":"Tuncay","family":"Sahutoglu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taner","family":"Basturk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tamer","family":"Sakaci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yener","family":"Koc","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elbis","family":"Ahbap","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mustafa","family":"Sevinc","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ekrem","family":"Kara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cuneyt","family":"Akgol","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Feyza Bayraktar","family":"Caglayan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdulkadir","family":"Unsal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamed R.","family":"Daha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-22-20210226","doi-asserted-by":"crossref","first-page":"1676","DOI":"10.1056\/NEJMra0902814","article-title":"Atypical hemolytic\u2013uremic syndrome","volume":"361","author":"Noris","year":"2009","journal-title":"N Engl J Med"},{"key":"R2-22-20210226","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1053\/j.ajkd.2015.03.040","article-title":"Glomerular diseases dependent on complement activation, including atypical hemolytic uremic syndrome, membranoproliferative glomerulonephritis, and c3 glomerulopathy: Core Curriculum 2015","volume":"66","author":"Noris","year":"2015","journal-title":"Am J Kidney Dis"},{"key":"R3-22-20210226","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1016\/j.semnephrol.2013.08.003","article-title":"Atypical hemolytic uremic syndrome","volume":"33","author":"Kavanagh","year":"2013","journal-title":"Semin Nephrol"},{"key":"R4-22-20210226","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1056\/NEJMc0808527","article-title":"Eculizumab for atypical hemolytic\u2013uremic syndrome","volume":"360","author":"N\u00fcrnberger","year":"2009","journal-title":"N Engl J Med"},{"key":"R5-22-20210226","doi-asserted-by":"crossref","first-page":"2169","DOI":"10.1056\/NEJMoa1208981","article-title":"Terminal complement inhibitor eculizumab in atypical hemolytic\u2013uremic syndrome","volume":"368","author":"Legendre","year":"2013","journal-title":"N Engl J Med"},{"key":"R6-22-20210226","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1053\/j.ajkd.2014.01.434","article-title":"Discontinuation of eculizumab maintenance treatment for atypical hemolytic uremic syndrome: a report of 10 cases","volume":"64","author":"Ardissino","year":"2014","journal-title":"Am J Kidney Dis"},{"key":"R7-22-20210226","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1038\/ki.2014.423","article-title":"Efficacy and safety of eculizumab in atypical hemolytic uremic syndrome from 2-year extensions of phase 2 studies","volume":"87","author":"Licht","year":"2015","journal-title":"Kidney Int"},{"key":"R8-22-20210226","doi-asserted-by":"crossref","first-page":"1844","DOI":"10.2215\/CJN.02210310","article-title":"Relative role of genetic complement abnormalities in sporadic and familial aHUS and their impact on clinical phenotype","volume":"5","author":"Noris","year":"2010","journal-title":"Clin J Am Soc Nephrol"},{"key":"R9-22-20210226","doi-asserted-by":"crossref","first-page":"e93","DOI":"10.1111\/j.1432-2277.2012.01497.x","article-title":"Eculizumab for the treatment of two recurrences of atypical hemolytic uremic syndrome in a kidney allograft","volume":"25","author":"Alachkar","year":"2012","journal-title":"Transpl Int"},{"key":"R10-22-20210226","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1053\/j.ajkd.2015.04.010","article-title":"Discontinuation of eculizumab treatment in atypical hemolytic uremic syndrome: an update","volume":"66","author":"Ardissino","year":"2015","journal-title":"Am J Kidney Dis"},{"key":"R11-22-20210226","doi-asserted-by":"crossref","first-page":"1715","DOI":"10.1182\/blood-2014-02-558296","article-title":"Dynamics of complement activation in aHUS and how to monitor eculizumab therapy","volume":"124","author":"Noris","year":"2014","journal-title":"Blood"},{"key":"R12-22-20210226","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1038\/ki.2013.447","article-title":"Anti-factor H autoantibody-associated hemolytic uremic syndrome: the earlier diagnosed and treated, the better","volume":"85","author":"Loirat","year":"2014","journal-title":"Kidney Int"},{"key":"R13-22-20210226","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1053\/j.ajkd.2009.12.026","article-title":"Pulse cyclophosphamide therapy and clinical remission in atypical hemolytic uremic syndrome with anti-complement factor H autoantibodies","volume":"55","author":"Boyer","year":"2010","journal-title":"Am J Kidney Dis"},{"key":"R14-22-20210226","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1007\/s00467-013-2558-9","article-title":"Long-term remission of atypical HUS with anti-factor H antibodies after cyclophosphamide pulses","volume":"29","author":"Sana","year":"2014","journal-title":"Pediatr Nephrol"},{"key":"R15-22-20210226","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1038\/ki.2013.373","article-title":"Prompt plasma exchanges and immunosuppressive treatment improves the outcomes of anti-factor H autoantibody-associated hemolytic uremic syndrome in children","volume":"85","author":"Sinha","year":"2014","journal-title":"Kidney Int"},{"key":"R16-22-20210226","doi-asserted-by":"crossref","first-page":"2180","DOI":"10.1681\/ASN.2010030315","article-title":"Clinical features of anti-factor H autoantibody-associated hemolytic uremic syndrome","volume":"21","author":"Dragon-Durey","year":"2010","journal-title":"J Am Soc Nephrol"},{"key":"R17-22-20210226","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1111\/ajt.12077","article-title":"Complement genes strongly predict recurrence and graft outcome in adult renal transplant recipients with atypical hemolytic and uremic syndrome","volume":"13","author":"Le Quintrec","year":"2013","journal-title":"Am J Transplant"},{"key":"R18-22-20210226","doi-asserted-by":"crossref","first-page":"2327","DOI":"10.1007\/s00467-012-2283-9","article-title":"Eculizumab therapy in a child with hemolytic uremic syndrome and CFI mutation","volume":"27","author":"Cayc\u0131","year":"2012","journal-title":"Pediatr Nephrol"},{"key":"R19-22-20210226","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1007\/s00467-013-2416-9","article-title":"Neurologic involvement in atypical hemolytic uremic syndrome and successful treatment with eculizumab","volume":"28","author":"Gulleroglu","year":"2013","journal-title":"Pediatr Nephrol"},{"key":"R20-22-20210226","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1007\/s00277-012-1622-z","article-title":"Relapse of aHUS after discontinuation of therapy with eculizumab in a patient with aHUS and factor H mutation","volume":"92","author":"Carr","year":"2013","journal-title":"Ann Hematol"},{"key":"R21-22-20210226","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1007\/s00277-013-1972-1","article-title":"Successful discontinuation of eculizumab therapy in a patient with aHUS","volume":"93","author":"Pu","year":"2014","journal-title":"Ann Hematol"},{"key":"R22-22-20210226","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1053\/j.ajkd.2014.04.039","article-title":"Discontinuation of eculizumab maintenance treatment for atypical hemolytic uremic syndrome","volume":"65","author":"Wetzels","year":"2015","journal-title":"Am J Kidney Dis"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000004330","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,14]],"date-time":"2021-05-14T02:29:38Z","timestamp":1620959378000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00005792-201608020-00022"}},"subtitle":["Case report and review of the literature"],"short-title":[],"issued":{"date-parts":[[2016,8]]},"references-count":22,"journal-issue":{"issue":"31","published-print":{"date-parts":[[2016]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000004330","relation":{},"ISSN":["0025-7974"],"issn-type":[{"value":"0025-7974","type":"print"}],"subject":[],"published":{"date-parts":[[2016,8]]}}}